The results reported a 6.0%, 6.8%, 9.1%, 9.7%, and 10.8% decrease in body weight for the groups receiving cagrilintide in doses of 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, and 4.5 mg, respectively [1]
The clock starts now, and you have 28 days of reliable potency
Neither Sage Canaday or Mike McKnight (or even WADA, for that matter) know if BPC-157 is a PED
Timing: Evening dosing is commonly preferred to better align with natural growth hormone rhythms
None of the combination-specific risks have been characterized in a human trial because that trial does not exist
Timing Optional Monitoring guidance is pathway-based because compound-specific clinical monitoring standards for AOD-9604 are not established